Evidence map›Paper›PMID 36613601›Full record

ArticleInternational journal of molecular sciences2022

Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification.

Galina Zakharova, Victor Efimov, Mikhail Raevskiy, Pavel Rumiantsev, Alexander Gudkov, Oksana Belogurova-Ovchinnikova, Maksim Sorokin, Anton Buzdin

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Sprouty in Tumors of the Nervous System.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Galina ZakharovaWorld-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, 119048 Moscow, Russia.ORCID 0000-0002-2548-8511
Victor EfimovWorld-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, 119048 Moscow, Russia.
Mikhail RaevskiyWorld-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, 119048 Moscow, Russia.
Pavel RumiantsevMultidisciplinary Medical Center, Group of Clinics, 194044 Saint-Petersburg, Russia.
Alexander GudkovWorld-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, 119048 Moscow, Russia.
Oksana Belogurova-OvchinnikovaMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.ORCID 0000-0002-4741-0600
Maksim SorokinWorld-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, 119048 Moscow, Russia.ORCID 0000-0001-7685-3446
Anton BuzdinWorld-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, 119048 Moscow, Russia.
Sechenov University · RUMoscow Institute of Physics and Technology · RU

Funding

ERA-NET RUS Plus Program (GOTICS Project) and the Russian Foundation for Basic Research 20-515-76007
6 · The paper itself

Abstract

In 2021, the fifth edition of the WHO classification of tumors of the central nervous system (WHO CNS5) was published. Molecular features of tumors were directly incorporated into the diagnostic decision tree, thus affecting both the typing and staging of the tumor. It has changed the traditional approach, based solely on histopathological classification. The Cancer Genome Atlas project (TCGA) is one of the main sources of molecular information about gliomas, including clinically annotated transcriptomic and genomic profiles. Although TCGA itself has played a pivotal role in developing the WHO CNS5 classification, its proprietary databases still retain outdated diagnoses which frequently appear incorrect and misleading according to the WHO CNS5 standards. We aimed to define the up-to-date annotations for gliomas from TCGA's database that other scientists can use in their research. Based on WHO CNS5 guidelines, we developed an algorithm for the reclassification of TCGA glioma samples by molecular features. We updated tumor type and diagnosis for 828 out of a total of 1122 TCGA glioma cases, after which available transcriptomic and methylation data showed clustering features more consistent with the updated grouping. We also observed better stratification by overall survival for the updated diagnoses, yet WHO grade 3

Indexed as

Brain NeoplasmsCentral Nervous System NeoplasmsGliomaBiomarkers, TumorEpigenesis, GeneticGenomicsHumansIsocitrate DehydrogenaseMutationTranscriptomeWorld Health OrganizationBiomarkers, TumorIsocitrate Dehydrogenaseadult-type diffuse gliomascancer biomarkersclassification of CNS tumorsepigenetic profilesgenomicsglioblastomaTCGAThe Cancer Genome AtlastranscriptomicsWHO CNS5

Identifiers

PMID36613601
PMCPMC9820617
OpenAlexW4313505502

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.